Promise or reality? Consumers doubt cannabis rescheduling under the Trump era
Poll reveals that most consumers in the US do not believe the plant's rescheduling will be completed this year
Cannabis rescheduling in the United States continues to be surrounded by expectations, but for those following the sector closely, optimism does not seem to have reached the consumer. While the financial market monitors every regulatory move in Washington, perception among users remains marked by caution. According to the website Marijuana Moment, a new opinion poll shows that the majority of cannabis consumers do not believe Donald Trump's administration will complete, this year, the process of moving the plant from Schedule I to Schedule III of the Controlled Substances Act.
More than just a snapshot of public opinion, the survey highlights distrust regarding the pace of federal bureaucracy. Although the debate on rescheduling has advanced in recent months, the prevailing perception is that the process still faces administrative and political hurdles capable of postponing a final decision.
Market follows closely, consumers remain skeptical
According to reporting by Marijuana Moment, the skepticism reflects the complexity of the regulatory process in the United States. For many consumers, the combination of administration changes, political disputes, and technical requirements makes completing the measure in the short term unlikely.
This outlook is closely monitored by the global cannabis market. After all, any breakthrough in US federal policy tends to influence investments, legal certainty, and expansion strategies of companies operating in the segment across different countries.
The impact of Schedule III on the cannabis industry
If approved, rescheduling will remove cannabis from the category designated for substances considered to have no accepted medical use and a high potential for abuse. The change could represent a milestone for the industry, particularly by reducing the tax burden on companies in the sector and expanding possibilities for scientific research and the development of new medicines.
Even so, the survey reinforces the prevailing sentiment among consumers. According to Marijuana Moment, the majority does not believe the Trump administration will complete the rescheduling of controlled substances this year—an indication that, for the cannabis market, expectations remain tempered given the slowness of regulatory processes.
Source: Marijuana Moment.